Show Menu
Cheatography

Lung Cancer Cheat Sheet Cheat Sheet (DRAFT) by

This is a draft cheat sheet. It is a work in progress and is not finished yet.

One Minute Pitch

Lung tumors are highly hetero­gen­eous, with great variab­ility between individual patients, cancer types, and stages, as well as intra-­tumor hetero­gen­eity. This variab­ility poses a consid­erable challenge in identi­fying and validating clinically relevant lung cancer biomar­kers. Theref­ore­, s­pat­ial­ly-­mapped gene expression at the cellular level is crucial to understand the cell-t­o-cell intera­ctions in the tumor and the cellular makeup within the complex tumor microe­nvi­ronment (TME).

Key Selling Point

Assessment of predictive markers for lung cancer
When antibodies are not available e.g. ARNTL2
Charac­ter­ization of secreted proteins
Validation of transc­riptome data
Detection of lncRNAs in lung cancer - e.g. LINC00473 could be used as a surrogate biomarker for LKB1 in lung cancer samples.
Detection of lncRNAs in lung cancer - ACD60 NSCLC lncRNA study
Detection of immune cell checkpoint and functional lung cancer biomarkers in the TME - ACD 60 NSCLC immuno­-on­cology study

Marketing Materials

Lung Cancer related public­ati­ons: http:/­/bi­t.l­y/2­rtGXny
Scie­ntific Poster:
lncRNA in lung Cancer: Coming soon
Appl­ic­­ation note: "­­De­t­e­ction of immune cell checkpoint and functional markers in the tumor microe­­nv­i­r­onment by the RNA in situ hybrid­­iz­ation RNAscope® assay'
 

Lung Cancer Related Probes

AGER AGR2 AKT1 ANXA5 APBA1 APC BCL2 BIRC5 BRAF CA4 CADM1 CDH1 CDH13 CDKN1C CDKN2A CDKN2B CEACAM5 CEACAM6 CLCA2 CLDN18 CLIC5 COL11A1 CP CSF3 CXCL12 CXCL13 CYP1B1 DLC1 DSG3 DUSP6 EGFR ERBB2 ERBB3 FABP4 FHIT GPM6A GREM1 HGF HMMR HRAS IRF4 KRAS KRT14 KRT5 LCK LGSN MET MGMT MKI67 MLH1 MMD MMP1 MMP12 MMP9 MTHFR NF1 NFKB1 NKX2-1 OPCML PAX5 PRDM2 PTGS2 RASSF1 RASSF2 RB1 SCGB1A1 SFRP1 SFTA3 SFTPC SOSTDC1 SPINK1 SPP1 SPRR1A STAT1 STAT2 TCF21 TERT TGFB1 TNF TOP2A TOX3 TP53 VEGFA WIF1

Special Case: MET-delta 14 in lung cancer

Nearly all of the MET exon 14 mutations described to date cause skipping of MET exon 14 during pre-mRNA splicing.
Skipping of exon 14 in the MET gene results in impaired c-Met receptor degrad­ation, consti­tutive activation of the MET receptor, and oncogenic transf­orm­ation of MET.
This variant, referred to as METΔ14, is a gain-o­f-f­unction phenotype that can respond positively to some therap­eutics and is present in a variety of cancer types, partic­ularly lung cancer, where it is present in approx­imately 3% of non-small cell lung carcinoma cases.
Detection of altera­tions in MET exon 14 could aid in identi­fying patients likely to benefit from MET inhibi­tors. The BaseScope assay for exon junction detection is the solution here.

MET-Delta 14 probe design

   

Help Us Go Positive!

We offset our carbon usage with Ecologi. Click the link below to help us!

We offset our carbon footprint via Ecologi